版本:
中国

BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test

April 27 Myriad Genetics Inc:

* Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment

* Says financial terms of deal were not disclosed.

* Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐